--News Direct--
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X, a treatment for obstructive sleep apnoea (OSA). The investigators, Dr John D Hudson of FutureSearch Trials of Neurology in Austin, Texas, and Dr Russell Rosenberg of Neurotrials Research Inc in Atlanta, Georgia, will play a crucial role overseeing the first clinical trial sites, handling submissions to the FDA and obtaining ethics approval from Institutional Review Boards.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
Jonathan@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/incannex-appoints-principal-investigators-for-pivotal-ihl-42x-trial-508961464
